Latest News

At a Dermatology Times Case-Based Roundtable in Las Vegas, clinicians compared topical corticosteroids, newer nonsteroidal agents, and systemic therapy across adult and adolescent AD cases.

This review of the latest dermatological studies includes insights on JAKs in severe HS, reactive cutaneous capillary endothelial proliferation in esophageal SCC, PN treatment preferences, and more.

Envudeucitinib achieved PASI 100 in 54% of continuously treated patients at 48 weeks in the phase 3 ONWARD3 extension study.

See how precision biologics—dupilumab, IL-13/IL-31 blockers, JAK inhibitors, and omalizumab—change treatment for atopic dermatitis and chronic spontaneous urticaria.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

In this episode, Miles Harrison and Brian Pilcher, PhD, explain investigational ECM injectables that aim to restore tissue scaffold for wound healing and address post–GLP-1 skin quality changes beyond fillers.

FDA clears Labcorp’s NGS tissue test to quickly spot BRAF V600E/K melanoma, guiding targeted BRAF/MEK therapy selection in days.

Sonelokimab met the primary end point in phase 3 IZAR-1, with 42.1% of biologic-naive patients achieving ACR50 at week 16.

HS microbiome studies fuel probiotic hype, but a new review finds evidence too thin for routine use and highlights key research gaps.

Does facial massage with a gua sha improve skin or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

New oral TYK2 inhibitor shows rapid PASI 75/90 skin clearance in phase 2 plaque psoriasis study, with encouraging safety.

The accelerated FDA approval, based on Replimune's phase 2 IGNYTE trial data, gives clinicians a new second-line option for adults with advanced melanoma progressing after anti-PD-1 therapy.

Obesity may blunt biologic psoriasis gains, according to a 4,200‑patient meta‑analysis showing lower PASI responses, but weight alone shouldn’t drive drug choice.